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Abstract The cellular response to DNA damage involves
checkpoint controls that delay cell cycle progression in order to
provide time for repair of damaged DNA. Chk2/hCds1 is a
recently identified homolog of the yeast Cds1 kinase that is
involved in cell cycle checkpoint response to DNA damage. To
investigate the functions of Chk2/hCds1 in response to DNA
damage in mammalian cells, we established a stable human
kidney embryonic cell line (HEK-293) that expresses antisense
Chk2/hCds1 (Chk2AS) under the control of an inducible
promoter. Cells that express Chk2AS display defective S-phase
delay in response to DNA replication-mediated DNA damage
induced by the topoisomerase I inhibitor camptothecin. The
defective G2 checkpoint was also observed in Chk2AS cells
exposed to the DNA damaging agent VP-16 or Q-radiation.
Enhanced apoptosis was observed in Chk2AS cells after
exposure to Q-radiation or camptothecin. No p53 activation
was observed after DNA damage in HEK-293 or Chk2AS cells.
Our results indicate that perturbation of Chk2/hCds1 expression
adversely affects the S- and G2-phase checkpoints following
DNA damage or DNA replication block, and suggest that
reduced expression of Chk2/hCds1 might promote a p53-
independent apoptotic response. ß 2001 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Cell cycle checkpoints are signal transduction pathways
that ensure the time, sequence, and ¢delity of critical cell cycle
events and orchestrate cellular responses to environmentally
induced genotoxic stress. DNA damage induced by ionizing
radiation or chemotherapeutic agents trigger checkpoint acti-
vation and delay cell cycle progression [1]. Such a delay in cell
cycle would presumably allow time to repair damaged DNA
or to complete DNA replication before entry into mitosis [2].
Disruption of cell cycle checkpoint control leads to increased
genomic instability, and enhances the predisposition to cancer
[3]. A majority of human cancers have a defect in the G1
checkpoint because of mutations of the p53 tumor suppressor
gene. Compared to the G1 checkpoint, less is known about
the genes that contribute to G2- and S-phase checkpoint reg-
ulation.
Chk2/hCds1, a mammalian homolog of the Saccharomyces
cerevisiae Rad53 and Schizosaccharomyces pombe cds1 has
been recently identi¢ed by several groups [4^7]. Chk2/hCds1
is implicated as an important component in DNA damage
response pathways. In human cells, Chk2/hCds1 has been
shown to be phosphorylated and activated in response to ion-
izing radiation in an ataxia telangiectasia mutated (ATM)-de-
pendent manner, as well as in response to UV and replication
block in an ATM-independent manner [4^7]. Chk2/hCds1,
like its yeast counterpart cds1, can phosphorylate Cdc25C
on the inhibitory phosphorylation site S216 in vitro, and
thus may activate the G2 checkpoint by inactivation of
Cdc2 through Cdc25C [4^7]. Although Chk2/hCds1 has
been shown to be activated by DNA damage, its role in the
checkpoint control remains to be elucidated in human cells.
While the preparation of this manuscript was in progress,
Hirao et al. have shown that Chk2/hCds1 is required for
cell cycle G2 checkpoint because Chk2/hCds1-de¢cient mouse
embryonic stem (ES) cells fail to maintain a G2 arrest after
DNA damage [8]. In the study that follows, we generated a
cell line that conditionally expresses antisense Chk2/hCds1
(Chk2AS) and investigated the role of Chk2/hCds1 in regulat-
ing cell cycle checkpoints and apoptotic response in human
cells. Our results indicate that Chk2/hCds1 plays a role in S-
and G2-phase checkpoints in response to DNA damage or
replication block. We demonstrate that p53 is inactive in
HEK-293 cells and that reduced expression of Chk2/hCds1
in these cells promotes apoptosis, suggesting that Chk2/
hCds1 de¢ciency might lead to enhanced apoptosis in p53-
defective cells.
2. Materials and methods
2.1. The ecdysone-inducible expression system for Chk2AS expression
To develop a cell line that conditionally expresses Chk2AS, we used
the ecdysone-inducible mammalian expression system (Invitrogen,
Carlsbad, CA, USA). The expression system is based on the hetero-
dimeric ecdysone receptor of Drosophila. On binding of ecdysone, the
receptor activates an ecdysone-responsive promoter, which promotes
high-level expression of the gene. A human Chk2/hCds1 cDNA was
ligated into the pIND expression vector in the antisense orientation.
The resulting pIND-Chk2/hCds1AS vector was transfected into a
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human embryonic kidney cell line that constitutively expresses the
ecdysone receptor (EcR-293) (Invitrogen, Carlsbad, CA, USA) by
means of Fugene (Boehringer Mannheim, Indianapolis, IN, USA).
EcR-293 cells transfected with pIND empty vector plasmid DNA
were used as a control. Stable clones were selected by limiting dilution
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 10%
fetal calf serum, 600 Wg/ml G418 and 400 Wg/ml zeocin. To determine
the expression of Chk2/hCds1 in transfected cells, the ecdysone analog
ponasteron A (PonA; Invitrogen) was added to the cultures to a ¢nal
concentration of 5 WM, and cells were collected after 24 h for Western
blot analysis. The resulting cell line that expresses reduced Chk2/
hCds1 was herein named Chk2AS.
2.2. Cell cycle analysis
Cell cycle assays were performed as described previously [9]. Brie£y,
cells were harvested and ¢xed in 70% ethanol. The ¢xed cells were
then stained with propidium iodide (50 Wg/ml) after treatment with
RNase (5 Wg/ml). The stained cells were analyzed for DNA content by
£uorescence-activated cell sorting (FACS) in a FACScan (SOBR
model, Becton Dickinson Instrument, San Jose, CA, USA). Cell cycle
fractions were quanti¢ed with CellQuest (Becton Dickinson).
2.3. Protein analysis
Cell lysates were prepared as reported previously [9]. Brie£y, cells
were lysed with cell lysis bu¡er (0.3% NP-40, 1 mM EDTA, 50 mM
Tris^HCl, pH 7.4, 2 mM EGTA, 10% Triton X-100, 150 mM NaCl,
25 mM NaF, 1 mM Na3VO4; 2 mM AEBSF, 5 Wg/ml aprotinin,
1 Wg/ml leupeptin) for 30 min on ice, and the lysates were clari¢ed
by centrifugation at 12 000Ug for 15 min at 4‡C. Protein concentra-
tion was quanti¢ed by the protein assay (Bio-Rad, Hercules, CA,
USA) and protein samples (100 Wg) were separated by SDS^PAGE
(12% polyacrylamide) and transferred onto Immobilon membranes
(Millipore, Bedford, MA, USA). Chk2/hCds1 or p53 proteins were
identi¢ed using anti-Chk2/hCds1 or anti-p53 primary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and reactive
bands were visualized using the enhanced chemiluminescence detec-
tion system (NEN Life Science Products, Boston, MA, USA).
2.4. Apoptosis detection
Apoptosis was assessed by £ow cytometry using a FITC-conjugated
anti-PARP (poly(ADP-ribose)polymerase) cleavage site-speci¢c anti-
body (Biosource, Camarillo, CA, USA) according to the manufactur-
er’s instructions. Brie£y, cells were treated with the indicated stimuli
to induce apoptosis. The cells were washed with phosphate-bu¡ered
saline (PBS) twice and lifted with 2 mM EDTA. Once detached, the
cells were washed once with PBS and ¢xed with PBS containing 4%
paraformaldehyde for 20 min at 4‡C, and permeabilized in PBS con-
taining 0.1% saponin for 10 min. The cells were then incubated with
10 Wl of FITC^PARP antibody in 100 Wl PBS for 30 min at room
temperature. After washing, the cells were resuspended in PBS and
analyzed by FACS.
3. Results and discussion
3.1. Inhibition of Chk2/hCds1 protein expression by antisense
transfection
To generate a cell line that expresses reduced Chk2/hCds1
protein conditionally, we stably transfected an ecdysone-in-
ducible Chk2AS expression vector into EcR-293 cells. The
resulting clones were treated with the ecdysone analogue
PonA to induce Chk2AS expression. Shown in Fig. 1 is the
Western blot analysis of Chk2/hCds1 protein expression in
stably transfected EcR-293 cells after 24 and 48 h treatment
with PonA (5 WM). Chk2/hCds1 expression was reduced to
50% after 24 h of PonA treatment and no further decrease
was observed after 48 h treatment. PonA treatment of mock-
transfected cells did not result in a decrease in Chk2/hCds1
expression (data not shown). The EcR-293 cells that are in-
duced to express antisense Chk2/hCds1 are named Chk2AS
throughout this report.
3.2. Inhibition of Chk2/hCds1 expression leads to
impaired S and G2 checkpoints
Chk2/hCds1 and its yeast homolog cds1 have been sug-
gested to be important in both DNA damage and replication
checkpoints [5,10^13]. To determine the requirement of Chk2/
hCds1 for cell cycle checkpoint regulation, we ¢rst examined
whether reduced expression of Chk2/hCds1 a¡ects S-phase
arrest caused by the topoisomerase I inhibitor camptothecin
(CPT). CPT is know to form topoisomerase I cleavage com-
plexes which are converted into DNA double-strand breaks
by DNA replication [14]. Thus, CPT was used to activate a
replication checkpoint in the S phase [15]. A study by Cha-
turvedi et al. [6] indicated that topoisomerase I inhibitor top-
otecan, an analog of CPT, can activate Chk2 in human cells.
To study the role of Chk2/hCds1 on the S-phase checkpoint,
cells were treated with PonA for 24 h to express Chk2AS
before further exposure to 100 nM CPT. FACS analysis
showed a similar cell cycle pro¢le 24 h after treatment of
control cells with PonA, indicating that this compound did
not perturb the cell cycle distribution in the absence of DNA
damage. 8 h after CPT treatment, approximately 55% of con-
trol cells were accumulated in S phase, as measured by FACS
analysis. By contrast, the S-phase population was reduced to
Fig. 1. Inhibition of Chk2/hCds1 protein expression after induction
of Chk2AS. The EcR-293 cells that were transfected with a pIND
plasmid containing Chk2AS cDNA were cultured in DMEM con-
taining 800 Wg/ml G418 and 400 Wg/ml zeocin. A: Cells were treated
with or without 5 WM PonA for 24 and 48 h, and cell extracts were
separated by SDS gel electrophoresis, transferred to a membrane,
and blotted with anti-Chk2/hCds1 antibody. PCNA was used as a
loading control. B: Quantitation of the data presented in (A).
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32% in cells expressing Chk2AS (Fig. 2). 10 h after CPT re-
moval, cells were arrested in S and G2. Decreased S-phase
arrest was observed in Chk2AS cells both in the presence
and absence of nocodazole, indicating that Chk2/hCds1
down-regulation enabled the cells to progress through the S
phase. These results suggest that Chk2AS cells have defective
S-phase arrest in response to CPT treatment, implying a role
of Chk2/hCds1 in the replication checkpoint. Very recently,
an independent study also demonstrated a role of Chk2 in S-
phase checkpoint regulation via Cdc25A phosphorylation [32].
Fig. 2. Attenuated S-phase checkpoint in cells that express Chk2AS.
The EcR-293 cells that were transfected with a pIND plasmid con-
taining Chk2AS cDNA were grown in the presence or absence of
PonA (5 WM) for 24 h before exposure to 100 nM of CPT. 8 h
after CPT treatment, CPT was removed, and cells were grown for
an additional 10 h in the presence or absence of nocodazole (Noc).
A: Flow cytometry analyses (propidium iodide staining of DNA).
The positions of the G1, S, and G2 populations have been high-
lighted in the control sample, and the DNA content of G1 and G2
cells are labeled as 2N and 4N, respectively. B: Quantitation of the
£ow histograms presented as percentages of cells in G1, S and G
phases.
6
Fig. 3. Cells that express Chk2AS are defective for G2 checkpoint after exposure to CPT or VP-16. Cells grown in the presence or absence of
PonA were harvested at the indicated times after drug treatment and analyzed by £ow cytometry. A: Cells were treated with CPT (20 nM) or
VP-16 (2 and 10 WM) for 24 h. B: Time-course analysis of cell cycle progression for cells treated with 6 WM VP-16.
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To determine whether Chk2/hCds1 is required for G2
checkpoint, cells were subjected to continuous treatment
with low concentration of CPT, which produces primarily
G2 delay with minimal S-phase e¡ect. 24 h after CPT treat-
ment (20 nM), V70% of control cells were arrested at the
G2 phase with a 4N DNA content, as shown by FACS
analysis (Fig. 3A). By contrast, the percentage of cells in
G2 was reduced to 44% when cells were induced by PonA
to express Chk2AS (Fig. 3A). To expand our analysis to
other agents that cause DNA damage by di¡erent mecha-
nisms, cells were subjected to VP-16, a known topoisomerase
II inhibitor that arrests cells in G2 by causing DNA double-
strand breaks. As anticipated, 24 h after VP-16 treatment,
the control cells were arrested in G2 in a dose-dependent
manner with 76% of cells in G2 at 10 WM VP-16. By con-
trast, cells that express Chk2AS had a marked decrease in
their G2 accumulation (50%), and a corresponding increase
of cells in G1 from 8 to 24%. A time-course analysis of cell
cycle response to VP-16 showed that both control cells and
Chk2AS cells appeared to initiate a G2 arrest similarly, with
74 and 70% of cells in G2 by 16 h after DNA damage, re-
spectively (Fig. 3B). However, at later times, Chk2AS cells
prematurely escaped from the G2 checkpoint, as seen by the
decrease of cells in G2 to 62% (at 24 h) and 24% (at 30 h), and
a corresponding increase of cells in G1. In contrast, the con-
trol cells remained arrested at G2 (Fig. 3B). Similar results
were observed in Q-radiation-treated cells (data not shown).
These results suggest that initiation of the G2 checkpoint in
response to DNA damage was independent of Chk2/hCds1, as
both control and Chk2AS cells arrested in G2 with similar
kinetics. However, sustaining of the G2 checkpoint appears to
require Chk2/hCds1, as the Chk2AS cells failed to maintain
the G2 arrest. While our experiments were in progress, a study
by Hirao et al. reported that Chk2-de¢cient mouse ES cells
failed to maintain G2 arrest after DNA damage [8], which is
consistent with our observations. Furthermore, a more recent
study by the same group using a similar approach has sug-
gested that another checkpoint protein kinase Chk1 is re-
quired for initiating the G2 checkpoint following DNA dam-
age [16]. Taken together, these data suggest a model in which
both Chk1 and Chk2/hCds1 are required for the DNA dam-
age-induced G2 checkpoint. While Chk1 would be responsible
for the initiation of the G2 checkpoint in response to DNA
damage, Chk2/hCds1 would be required to sustain it. Our
results provide the ¢rst support for this hypothesis in human
cells.
We currently do not know the molecular basis by which
reduced expression of Chk2/hCds1 contributes to the inability
to maintain the S and G2 arrest. Chk2/hCds1 has been shown
to phosphorylate Cdc25C on Ser216 in vitro [4,5], suggesting
(but not proving) that Chk2/hCds1 may regulate the DNA
damage-induced G2 checkpoint by inactivating Cdc2 kinase
through Cdc25C. Our preliminary data, however, showed no
signi¢cant di¡erence in Cdc2 kinase activity after DNA dam-
age between control cells and Chk2AS cells (data not shown).
We do not currently exclude the possibility that the experi-
mental conditions in our system are not optimized. However,
it is likely that Chk2/hCds1 may target separate pathways to
cause cell cycle arrest. Indeed, recent evidence shows that
considerable redundancy exists in the regulation of DNA
damage-induced G2 checkpoint [17]. A recent study reported
that Chk2/hCds1 activity is not necessarily correlated with
Cdc2 activity, suggesting that Chk2/hCds1 may not target
Cdc25C for G2 regulation [18]. This implies that either the
deregulation of Chk2/hCds1 in our system is not su⁄cient to
enhance the tightly regulated Cdc2 activity or that Chk2/
hCds1 is not only targeting Cdc25C physiologically. Further-
more, Cdc25C phosphorylation in vivo can be completely
abolished by the Chk1 inhibitor UCN-01 (7-hydroxystauro-
sporine) [19,20], implying that Chk2/hCds1 may not be the
sole kinase for Cdc25C in vivo. Taken together, it is tempting
to speculate that Chk2/hCds1 kinase may regulate the G2
checkpoint through substrate(s) other than the Cdc25C^
Cdc2 regulatory pathway. This possibility is currently being
investigated. Regardless of the mechanism, our data demon-
strate the importance of Chk2/hCds1 in the G2 checkpoint
control, as loss of this checkpoint in cancer cells might con-
tribute to the tumorigenesis [21].
Fig. 4. Inhibition of Chk2/hCds1 expression results in enhanced apoptosis induced by IR and CPT. Chk2AS cells were cultured in the presence
or absence of 5 WM PonA for 24 h before exposure to IR (5 and 10 Gy) or CPT (1 and 2 WM). 24 h after treatment, cells were harvested and
stained with FITC-conjugated PARP antibody for £ow cytometry analysis. The percentages of positive staining cells are indicated.
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3.3. Inhibition of Chk2/hCds1 expression results in enhanced
apoptosis in p53-inactive HEK-293 cells
During apoptosis, the activation of a group of caspases,
such as caspase-3, and subsequent cleavage of cellular sub-
strates, such as PARP, are crucial components of the cell
death pathways [22]. Several recent reports indicate that
Chk2/hCds1 can activate p53 [8,23,24], and thus promote
p53-mediated apoptosis [8]. To examine the ability of Chk2AS
cells to undergo apoptosis, cells were treated with Q-irradiation
or CPT. 24 h after treatment, cells were harvested, ¢xed and
stained for PARP cleavage using FITC-conjugated PARP
antibody. Cells were then analyzed by £ow cytometry. The
appearance of the FITC^PARP Ab-positive cells was used
to measure levels of apoptosis. Compared to control cells,
Chk2AS cells exhibited a high level of £uorescence intensity
after treatment with both ionizing radiation and CPT (Fig. 4).
These data indicate that cells expressing reduced levels of
Chk2/hCds1 are more susceptible to DNA damage-induced
apoptosis.
It has been reported by Hirao et al. that Chk2/hCds1 can
promote apoptosis by activating p53 as a result of p53 phos-
phorylation on Ser20, and that Chk2-null ES cells exhibit re-
sistance to apoptosis in response to DNA damage due to loss
of p53 activation [8]. This observation appears to be contra-
dictory to our results. However, p53 in adenovirus-trans-
formed HEK-293 cells has been demonstrated not to be func-
tional [25^27]. Consistently, with observed high levels of p53
in HEK-293 cells, there was no elevation of p53 protein levels
following Q-irradiation (Fig. 5). Furthermore, no detectable
increase of p53 downstream targets, such as p21 and Bax,
were observed in irradiated HEK-293 cells (data not shown).
In Chk2-null ES cells, loss of p53 activation by Chk2 leads to
a decreased susceptibility to apoptosis when compared to the
wild-type ES cells that hold functional p53 [8] ^ a similar
phenotype when comparing p53 wild-type to p53 mutant cells.
However, in HEK-293 cells that are p53 inactive already,
deregulation of Chk2/hCds1 will result in de¢cient S and G2
checkpoints, thus enhancing apoptosis in a p53-independent
manner. Our data provide the ¢rst evidence that deregulation
of Chk2/hCds1 in p53-inactive cells contributes to enhanced
apoptosis. Thus, our data, combined with the report by Hirao
et al. [8], further suggest a central role of p53 in determining
the sensitivity to apoptosis when Chk2/hCds1 is de¢cient.
Down-regulation of Chk2/hCds1 in cells with functional p53
would prevent the induction of p53-mediated apoptosis. How-
ever, down-regulation of Chk2/hCds1 in cells with defective
p53 function would cause primarily de¢cient G2 checkpoint,
and thus promote apoptosis in a p53-independent manner. It
is well known that G2 checkpoint abrogators, such as ca¡eine
or UCN-01, selectively sensitize p53-de¢cient cells to radiation
or chemotherapeutic agents [9,20,28^31]. It is generally be-
lieved that p53-de¢cient cells, which lack G1, arrest enter
G2 with more damaged DNA compared to the p53 wild-
type cells. Thus, these cells would be more dependent on an
intact G2 checkpoint to repair DNA damage. Accordingly,
abrogation of S and G2 checkpoints would result in the great-
er radiosensitization of p53-de¢cient cells. The current ¢nd-
ings reported here support this view and further suggest that a
therapeutic gain might be achieved in the treatment of tumors
harboring p53 mutations by targeting Chk2/hCds1. Therefore,
it seems rational to develop Chk2/hCds1 inhibitors that can
be used to pharmacologically abrogate the S and G2 check-
points and enhance the sensitivity to chemotherapeutic agents.
References
[1] Elledge, S.J. (1996) Science 274, 1664^1672.
[2] Lane, D.P. (1992) Nature 358, 15^16.
[3] Weinert, T. (1998) Cell 94, 555^558.
[4] Brown, A.L., Lee, C.H., Schwarz, J.K., Mitiku, N., Piwnica-
Worms, H. and Chung, J.H. (1999) Proc. Natl. Acad. Sci.
USA 96, 3745^3750.
[5] Matsuoka, S., Huang, M. and Elledge, S.J. (1998) Science 282,
1893^1897.
[6] Chaturvedi, P., Eng, W.K., Zhu, Y., Mattern, M.R., Mishra, R.,
Hurle, M.R., Zhang, X., Annan, R.S., Lu, Q., Faucette, L.F.,
Scott, G.F., Li, X., Carr, S.A., Johnson, R.K., Winkler, J.D. and
Zhou, B.B. (1999) Oncogene 18, 4047^4054.
[7] Blasina, A., de Weyer, I.V., Laus, M.C., Luyten, W.H., Parker,
A.E. and McGowan, C.H. (1999) Curr. Biol. 9, 1^10.
[8] Hirao, A., Kong, Y.Y., Matsuoka, S., Wakeham, A., Ruland, J.,
Yoshida, H., Liu, D., Elledge, S.J. and Mak, T.W. (2000) Science
287, 1824^1827.
[9] Shao, R.G., Cao, C.X., Shimizu, T., O’Connor, P.M., Kohn,
K.W. and Pommier, Y. (1997) Cancer Res. 57, 4029^4035.
[10] Murakami, H. and Okayama, H. (1995) Nature 374, 817^819.
[11] Murakami, H. and Nurse, P. (1999) Genes Dev. 13, 2581^2593.
[12] Zeng, Y., Forbes, K.C., Wu, Z., Moreno, S., Piwnica-Worms, H.
and Enoch, T. (1998) Nature 395, 507^510.
[13] Boddy, M.N., Furnari, B., Mondesert, O. and Russell, P. (1998)
Science 280, 909^912.
[14] Strumberg, D., Pilon, A.A., Smith, M., Hickey, R., Malkas, L.
and Pommier, Y. (2000) Mol. Cell. Biol. 20, 3977^3987.
[15] Shao, R.G., Cao, C.X., Zhang, H., Kohn, K.W., Wold, M.S. and
Pommier, Y. (1999) EMBO J. 18, 1397^1406.
[16] Liu, Q., Guntuku, S., Cui, X.S., Matsuoka, S., Cortez, D., Tam-
ai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A.,
Donehower, L.A. and Elledge, S.J. (2000) Genes Dev. 14, 1448^
1459.
[17] Passalaris, T.M., Benanti, J.A., Gewin, L., Kiyono, T. and Gallo-
way, D.A. (1999) Mol. Cell. Biol. 19, 5872^5881.
[18] Darbon, J.M., Penary, M., Escalas, N., Casagrande, F., Goubin-
Gramatica, F., Baudouin, C. and Ducommun, B. (2000) J. Biol.
Chem. 275, 15363^15369.
[19] Graves, P.R., Yu, L., Schwarz, J.K., Gales, J., Sausville, E.A.,
O’Connor, P.M. and Piwnica-Worms, H. (2000) J. Biol. Chem.
275, 5600^5605.
[20] Busby, E.C., Leistritz, D.F., Abraham, R.T., Karnitz, L.M. and
Sarkaria, J.N. (2000) Cancer Res. 60, 2108^2112.
[21] Bell, D.W., Varley, J.M., Szydlo, T.E., Kang, D.H., Wahrer,
D.C., Shannon, K.E., Lubratovich, M., Verselis, S.J., Isselbach-
er, K.J., Fraumeni, J.F., Birch, J.M., Li, F.P., Garber, J.E. and
Haber, D.A. (1999) Science 286, 2528^2531.
[22] Thornberry, N.A. and Lazebnik, Y. (1998) Science 289, 1312^
1316.
[23] Chehab, N.H., Malikzay, A., Appel, M. and Halazonetis, T.D.
(2000) Genes Dev. 14, 278^288.
[24] Shieh, S.Y., Ahn, J., Tamai, K., Taya, Y. and Prives, C. (2000)
Genes Dev. 14, 289^300.
Fig. 5. Lack of p53 induction in response to Q-radiation in EcR-293
cells. Cells were treated with 20 Gy IR and harvested at the indi-
cated times. Protein lysates were prepared and analyzed by Western
blot for p53 protein levels. PCNA analysis was included to assess
protein loading and transfer.
FEBS 25163 4-9-01
Q. Yu et al./FEBS Letters 505 (2001) 7^12 11
[25] Grand, R.J., Lecane, P.S., Owen, D., Grant, M.L., Roberts, S.,
Levine, A.J. and Gallimore, P.H. (1995) Virology 210, 323^334.
[26] Steegenga, W.T., van Laar, T., Riteco, N., Mandarino, A.,
Shvarts, A., van der Eb, A.J. and Jochemsen, A.G. (1996) Mol.
Cell. Biol. 16, 2101^2109.
[27] Steegenga, W.T., Shvarts, A., Riteco, N., Bos, J.L. and Jochem-
sen, A.G. (1999) Mol. Cell. Biol. 19, 3885^3894.
[28] Bracey, T.S., Williams, A.C. and Paraskeva, C. (1997) Clin. Can-
cer Res. 3, 1371^1381.
[29] Powell, S.N., DeFrank, J.S., Connell, P., Eogan, M., Pre¡er, F.,
Dombkowski, D., Tang, W. and Friend, S. (1995) Cancer Res.
55, 1643^1648.
[30] Wang, Q., Fan, S., Eastman, A., Worland, P.J., Sausville, E.A.
and O’Connor, P.M. (1996) J. Natl. Cancer Inst. 88, 956^965.
[31] O’Connor, P.M. (1997) Cancer Surv. 29, 151^182.
[32] Falck, J., Mailand, N., Syljuasen, R.G., Bartek, J. and Lukas, J.
(2001) Nature 410, 842^847.
FEBS 25163 4-9-01
Q. Yu et al./FEBS Letters 505 (2001) 7^1212
